European cancer mortality predictions for the year 2018 with focus on colorectal cancer Ann. Oncol. (IF 11.855) Pub Date : 2018-03-19 M Malvezzi, G Carioli, P Bertuccio, P Boffetta, F Levi, C La Vecchia, E Negri
We projected cancer mortality statistics for 2018 for the European Union (EU) and its six more populous countries, using the most recent available data. We focused on colorectal cancer.
Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients Ann. Oncol. (IF 11.855) Pub Date : 2018-03-14 M E Rodríguez-Ruiz, J L Perez-Gracia, I Rodríguez, C Alfaro, C Oñate, G Pérez, I Gil-Bazo, A Benito, S Inogés, A López-Diaz de Cerio, M Ponz-Sarvise, L Resano, P Berraondo, B Barbés, S Martin-Algarra, A Gúrpide, M F Sanmamed, C de Andrea, A M Salazar, I Melero
Combination immunotherapy has the potential to achieve additive or synergistic effects. Combined local injections of dsRNA analogues (mimicking viral RNA) and repeated vaccinations with tumor-lysate loaded dendritic cells shows efficacy against colon cancer mouse models. In the context of immunotherapy, radiotherapy can exert beneficial abscopal effects.
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected Ann. Oncol. (IF 11.855) Pub Date : 2018-03-10 F Pietrantonio, F Di Nicolantonio, A B Schrock, J Lee, F Morano, G Fucà, P Nikolinakos, A Drilon, J F Hechtman, J Christiansen, K Gowen, G M Frampton, P Gasparini, D Rossini, C Gigliotti, S T Kim, M Prisciandaro, J Hodgson, A Zaniboni, V K Chiu, M Milione, R Patel, V Miller, A Bardelli, L Novara, L Wang, S Pupa, G Sozzi, J Ross, M Di Bartolomeo, A Bertotti, S Ali, L Trusolino, A Falcone, F de Braud, C Cremolini
Recognition of rare molecular subgroups is a challenge for precision oncology and may lead to tissue-agnostic approval of targeted agents. Here we aimed to comprehensively characterize the clinical, pathological and molecular landscape of RET rearranged metastatic colorectal cancer (mCRC).
CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer Ann. Oncol. (IF 11.855) Pub Date : 2018-03-05 J Smeby, A Sveen, M A Merok, S A Danielsen, I A Eilertsen, M G Guren, R Dienstmann, A Nesbakken, R A Lothe
The prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer (CRC) varies with microsatellite instability (MSI) status. The gene expression-based consensus molecular subtypes (CMS) of CRC define molecularly and clinically distinct subgroups, and represent a novel stratification framework in biomarker analysis. We investigated the prognostic value of these mutations within the CMS groups.
Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intra-tumor heterogeneity over time Ann. Oncol. (IF 11.855) Pub Date : 2018-03-05 G Pasello, G Zago, F Lunardi, L Urso, I Kern, G Vlacic, F Grosso, M Mencoboni, G L Ceresoli, M Schiavon, F Pezzuto, A Pavan, S E Vuljan, P Del Bianco, P Conte, F Rea, F Calabrese
Tumor immune microenvironment (TME) plays a key role in malignant pleural mesothelioma (MPM) pathogenesis and treatment outcome, supporting a role of immune checkpoint inhibitors as anticancer approach. This study retrospectively investigated TME and PD-L1 expression in naïve MPM cases and their change under chemotherapy.
Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy Ann. Oncol. (IF 11.855) Pub Date : 2018-03-01 V E Baracos, L Arribas
Body composition, defined as the proportions and distribution of lean and fat tissues in the human body, is an emergent theme in clinical oncology. Severe muscle depletion (sarcopenia) is most easily overlooked in obese patients; the advent of secondary analysis of oncologic images provides a precise and specific assessment of sarcopenia. Here, we review the definitions, prevalence and clinical implications of sarcopenic obesity (SO) in medical and surgical oncology. Reported prevalence of SO varies due to the heterogeneity in the definitions and the variability in the cut points used to define low muscle mass and high fat mass. Prevalence of SO in advanced solid tumor patient populations average 9% (range 2.3%–14.6%) overall, and one in four (24.7%, range 5.9%–39.2%) patients with body mass index ≥ 30 kg/m2 are sarcopenic. SO is independently associated with higher mortality and higher rate of complications in systemic and surgical cancer treatment, across multiple cancer sites and treatment plans. These associations remain unexplained, however, it has been hypothesized that patients with sarcopenia are generally unfit and unable to tolerate stress. Another proposed mechanism relates to increased exposure to antineoplastic therapy, i.e. a large fat mass would be expected to inflate drug dose in BSA-based treatments, causing an increased rate of dose-limiting toxicity. Pharmacokinetic data are needed to confirm or refute this hypothesis. Old age, deconditioning, cancer progression, acute or chronic nonmalignant disease and drug side-effects are suggested causes of muscle loss, and it is unknown the degree to which this can be reversed. Sarcopenia can be readily detected before start of cancer treatment, however, clinical management protocols for SO patients require development. Studies of cancer treatment dose-modulation are in progress.
Muscle protein anabolism in advanced cancer patients: response to protein and amino acids support, and to physical activity Ann. Oncol. (IF 11.855) Pub Date : 2018-03-01 S Antoun, B Raynard
In the field of oncology, it is well recognized that a decrease in mass, density, strength, or function of skeletal muscle is associated to increased treatment toxicities and postoperative complications, as well as poor progression-free survival and overall survival. The ability of amino acids to stimulate protein synthesis in cancer patients is reduced. Considering nutritional intervention, this anabolic resistance could be in a part counteracted by increasing protein or by giving specific amino acids. In particular, Leucine might counteract this anabolic resistance not only by increasing substrate availability, but also by directly modulating the anabolic signal pathway. Few studies showed the possibility of increasing muscle protein synthesis by specific nutriments and/or by increasing amino acids or protein administration. In addition, whereas many studies provide evidence of a benefit of adapted physical activity in advanced cancer patients, it is difficult to specify the most appropriate type of exercise, and the optimum rhythm and intensity. Moreover, the benefits of physical activities and of protein support seem greater when it is started at the precachexia stage rather than at the cachexia stage, and their benefits are limited or nonexistent at the stage of refractory cachexia. Future approaches should integrate the combination of several complementary treatments in order to prevent (or improve) cachexia and/or sarcopenia in cancer patients.
Insulin resistance and body composition in cancer patients Ann. Oncol. (IF 11.855) Pub Date : 2018-03-01 R Dev, E Bruera, S Dalal
Cancer cachexia, weight loss with altered body composition, is a multifactorial syndrome propagated by symptoms that impair caloric intake, tumor byproducts, chronic inflammation, altered metabolism, and hormonal abnormalities. Cachexia is associated with reduced performance status, decreased tolerance to chemotherapy, and increased mortality in cancer patients. Insulin resistance as a consequence of tumor byproducts, chronic inflammation, and endocrine dysfunction has been associated with weight loss in cancer patients. Insulin resistance in cancer patients is characterized by increased hepatic glucose production and gluconeogenesis, and unlike type 2 diabetes, normal fasting glucose with high, normal or low levels of insulin. Cancer cachexia results in altered body composition with the loss of lean muscle mass with or without the loss of adipose tissue. Alteration in visceral adiposity, accumulation of intramuscular adipose tissue, and secretion of adipocytokines from adipose cells may play a role in promoting the metabolic derangements associated with cachexia including a proinflammatory environment and insulin resistance. Increased production of ghrelin, testosterone deficiency, and low vitamin D levels may also contribute to altered metabolism of glucose. Cancer cachexia cannot be easily reversed by standard nutritional interventions and identifying and treating cachexia at the earliest stage of development is advocated. Experts advocate for multimodal therapy to address symptoms that impact caloric intake, reduce chronic inflammation, and treat metabolic and endocrine derangements, which propagate the loss of weight. Treatment of insulin resistance may be a critical component of multimodal therapy for cancer cachexia and more research is needed.
MSR1 repeats modulate gene expression and affect risk of breast and prostate cancer Ann. Oncol. (IF 11.855) Pub Date : 2018-03-02 AM Rose, A Krishan, CF Chakarova, L Moya, S Chambers, M Hollands, JC Illingworth, SMG Williams, HE James, AZ Shah, CNA Palmer, A Chakravarti, JN Berg, J Batra, SS Bhattacharya
MSR1 repeats are a 36-38bp minisatellite element that have recently been implicated in the regulation of gene expression, through copy number variation (CNV).
Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study. Ann. Oncol. (IF 11.855) Pub Date : 2018-03-02 CKY Ng, G G Di Costanzo, N Tosti, V Paradiso, M Coto-Llerena, G Roscigno, V Perrina, C Quintavalle, T Boldanova, S Wieland, G Marino-Marsilia, M Lanzafame, L Quagliata, G Condorelli, M S Matter, R Tortora, M H Heim, L M Terracciano, S Piscuoglio
Hepatocellular carcinomas (HCCs) are not routinely biopsied, resulting in a lack of tumor materials for molecular profiling. Here we sought to determine if plasma-derived cell-free DNA (cfDNA) captures the genetic alterations of HCC in patients who have not undergone systemic therapy.
Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy Ann. Oncol. (IF 11.855) Pub Date : 2018-02-26 C E McCoach, G M Blumenthal, L Zhang, A Myers, S Tang, R Sridhara, P Keegan, R Pazdur, R C Doebele, D Kazandjian
Ann Oncol 2017; 28: 2707–2714 (doi: 10.1093/annonc/mdx414)
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol Ann. Oncol. (IF 11.855) Pub Date : 2018-02-26 Matthew R Sydes, Melissa R Spears, Malcolm D Mason, Noel W Clarke, David P Dearnaley, Johann S de Bono, Gert Attard, Simon Chowdhury, Bill Cross, Silke Gillessen, Zaf Malik, Rob Jones, Chris Parker, Alastair WS Ritchie, J Martin Russell, Robin Millman, David Matheson, Claire Amos, Clare Gilson, Alison Birtle, Susannah Brock, Lisa Capaldi, Prabir Chakraborti, Ananya Choudhury, Linda Evans, Daniel Ford, Joanna Gale, Stephanie Gibbs, Duncan Gilbert, Robert Hughes, Duncan McLaren, Jason Lester, Ashok Nikapota, Joe O’Sullivan, Omi Parikh, Clive Peedell, Andrew Protheroe, Sarah M Rudman, Richard Shaffer, Denise Sheehan, Matthew Simms, Narayanan Srihari, Räto Strebel, Santhanam Sundar, Shaun Tolan, David Tsang, Mohini Varughese, John Wagstaff, Mahesh KB Parmar, Nicholas D James
Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in STAMPEDE: a multi-arm multi-stage platform randomised controlled protocol recruiting patients with high-risk locally advanced or metastatic PCa starting long-term androgen deprivation therapy (ADT). The protocol provides the only direct, randomised comparative data of SOC+AAP vs SOC+DocP.
What is the optimal systemic treatment for men with metastatic, hormone- naive prostate cancer? A STOPCAP systematic review and network meta-analysis Ann. Oncol. (IF 11.855) Pub Date : 2018-02-23 CL Vale, DJ Fisher, I R White, J Carpenter, S Burdett, NW Clarke, K Fizazi, G Gravis, ND James, MD Mason, MKB Parmar, LH Rydzewska, CJ Sweeney, MR Spears, MR Sydes, JF Tierney
Our prior STOPCAP systematic reviews showed improved survival for men with metastatic hormone-naive prostate cancer (mHNPC) when abiraterone acetate plus prednisolone/prednisone (AAP) or docetaxel (Doc), but not zoledronic acid (ZA), were added to androgen deprivation therapy (ADT). Trial evidence also suggests a benefit of combining celecoxib (Cel) with ZA and ADT. To establish the optimal treatments, a network meta-analysis (NMA) was performed based on aggregate data (AD) from all available studies.
Physical activity in relation to risk of prostate cancer: a systematic review and meta-analysis Ann. Oncol. (IF 11.855) Pub Date : 2018-02-23 I N Benke, M F Leitzmann, G Behrens, D Schmid
Prostate cancer (PCa) is one of the most common cancers among men, yet little is known about its modifiable risk and protective factors. This paper aims to quantitatively summarize observational studies relating physical activity (PA) to PCa incidence and mortality.
Combined pathologic-genomic algorithm for early stage breast cancer improves cost-effective use of the 21-gene recurrence score assay. Ann. Oncol. (IF 11.855) Pub Date : 2018-02-23 M M Gage, W C Mylander, M Rosman, T Fujii, F Le Du, A Raghavendra, A. K Sinha, J R E Fernandez, A James, N T Ueno, L Tafra, R S Jackson
The 21-gene recurrence score (RS) [Oncotype DX®] partitions hormone receptor positive, node negative breast cancers into 3 risk groups for recurrence. The AAMC Model has previously been shown to accurately predict RS risk categories using standard pathology data. A Pathologic-Genomic (P-G) Algorithm then is presented using the AAMC model, and reserving the RS assay only for AAMC intermediate risk patients.
Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer Ann. Oncol. (IF 11.855) Pub Date : 2018-02-23 F Liang, S Zhang, Q Wang, W Li
The hazard ratio (HR) is used routinely to quantify the treatment effect for time-to-event endpoints in oncology trials, but its use requires that there be proportional hazards in the treatment arms. Non-proportional hazards are observed frequently in cancer immunotherapy trials due to the long-term survival and delayed clinical effect. Although values of HR are quoted in such trials they are not valid measures of outcome.
Phase I Study of the Checkpoint Kinase 1 Inhibitor GDC-0575 in Combination with Gemcitabine in Patients with Refractory Solid Tumors Ann. Oncol. (IF 11.855) Pub Date : 2018-02-23 A Italiano, J R Infante, G I Shapiro, K N Moore, P M LoRusso, E Hamilton, S Cousin, M Toulmonde, S Postel-Vinay, S Tolaney, E M Blackwood, S Mahrus, F V Peale, X Lu, A Moein, J Epler, K DuPree, M Tagen, E R Murray, J L Schutzman, J O Lauchle, A Hollebecque, J-C Soria
Checkpoint kinase 1 (Chk1) inhibition following chemotherapy-elicited DNA damage overrides cell cycle arrest and induces mitotic catastrophe and cell death. GDC-0575 is a highly-selective oral small-molecule Chk1 inhibitor that results in tumor shrinkage and growth delay in xenograft models. We evaluated the safety, tolerability, and pharmacokinetic (PK) properties of GDC-0575 alone and in combination with gemcitabine. Anti-tumor activity and Chk1 pathway modulation were assessed.
Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer Ann. Oncol. (IF 11.855) Pub Date : 2018-02-21 J Cortes, J Perez-Garcia, C Levy, P Gómez Pardo, H Bourgeois, S Spazzapan, N Martínez-Jañez, T-C Chao, M Espié, JM Nabholtz, X Gonzàlez Farré, V Beliakouski, J Román García, E Holgado, M Campone
There is no standard treatment after progression on second-line chemotherapy for metastatic breast cancer (MBC). We compared vinflunine with physician’s choice of alkylating agent (AA) for patients with heavily pretreated MBC.
Computational prediction of neoantigens: do we need more data or new approaches? Ann. Oncol. (IF 11.855) Pub Date : 2018-02-21 A C Eklund, Z Szallasi
Personalized cancer immunotherapy may benefit from improved computational algorithms for identifying neoantigens. Recent results demonstrate that machine learning can improve accuracy. Additional improvements may require more genomic data paired with in vitro T cell reactivity measurements, and more sophisticated algorithms that take into account T cell receptor specificity.
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines Ann. Oncol. (IF 11.855) Pub Date : 2018-02-20 M Aapro, Y Beguin, C Bokemeyer, M Dicato, P Gascón, J Glaspy, A Hofmann, H Link, T Littlewood, H Ludwig, A Österborg, P Pronzato, V Santini, D Schrijvers, R Stauder, K Jordan, J Herrstedt
Anaemia and iron deficiency (ID) are frequent complications in patients with solid tumours or haematological malignancies, particularly in patients treated with chemotherapeutic agents [1–3]. Frequently, anaemia is associated with fatigue, impaired physical function and reduced quality of life (QoL) [4–7]. Consequences of anaemia may include impaired response to cancer treatment and reduced overall survival (OS), even though a causal direct relationship has not yet been established [8, 9].
Quality of life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer. Ann. Oncol. (IF 11.855) Pub Date : 2018-02-16 M C Piccirillo, G Scambia, A Bologna, S Signoriello, I Vergote, K Baumann, D Lorusso, V Murgia, R Sorio, G Ferrandina, C Sacco, G Cormio, E Breda, S Cinieri, D Natale, G Mangili, C Pisano, S C Cecere, M Di Napoli, V Salutari, F Raspagliesi, L Arenare, A Bergamini, J Bryce, G Daniele, C Gallo, S Pignata, F Perrone
MITO-8 showed that prolonging platinum-free interval by introducing non-platinum-based chemotherapy (NPBC) does not improve prognosis of patients with partially platinum-sensitive recurrent ovarian cancer. Quality of life (QOL) was a secondary outcome.
Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple negative breast and serous ovarian cancers Ann. Oncol. (IF 11.855) Pub Date : 2018-02-14 NJ Birkbak, Y Li, S Pathania, A Greene-Colozzi, M Dreze, C Bowman-Colin, Z Sztupinszki, M Krzystanek, M Diossy, N Tung, PD Ryan, JE Garber, DP Silver, JD Iglehart, ZC Wang, D Szuts, Z Szallasi, AL Richardson
Platinum based therapy is an effective treatment for a subset of triple negative breast cancer and ovarian cancer patients. In order to increase response rate and decrease unnecessary use, robust biomarkers that predict response to therapy are needed.
Beyond Second-Line Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review Ann. Oncol. (IF 11.855) Pub Date : 2018-02-14 D Arnold, G W Prager, A Quintela, A Stein, S Moreno, N Mounedji, J Taieb
The optimal chemotherapeutic regimen for use beyond the second-line for patients with metastatic colorectal cancer (mCRC) remains unclear.
Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane Ann. Oncol. (IF 11.855) Pub Date : 2018-02-10 M Martin, M Campone, I Bondarenko, D Sakaeva, S Krishnamurthy, L Roman, L Lebedeva, J-C Vedovato, M Aapro
Capecitabine is an approved standard therapy for anthracycline- and taxane-pretreated locally advanced or metastatic breast cancer (BC). Vinflunine has demonstrated single-agent activity in phase II studies in this setting, and activity and tolerability when combined with capecitabine. We compared the combination of vinflunine plus capecitabine (VC) with single-agent capecitabine.
Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma Ann. Oncol. (IF 11.855) Pub Date : 2018-02-09 W Jurczak, P L Zinzani, G Gaidano, A Goy, M Provencio, Z Nagy, T Robak, K Maddocks, C Buske, S Ambarkhane, M Winderlich, M Dirnberger-Hertweck, R Korolkiewicz, K A Blum
This two-stage, phase IIa study (ClinicalTrials.gov: NCT01685008) investigated the antitumor activity and safety of MOR208, an Fc-engineered, humanized, CD19 antibody, in patients with relapsed or refractory (R-R) B-cell non-Hodgkin’s lymphoma (NHL). CD19 is broadly expressed across the B-lymphocyte lineage, including in B-cell malignancies, but not by hematological stem cells.
Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus IV paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy Ann. Oncol. (IF 11.855) Pub Date : 2018-02-09 Y-K Kang, M-H Ryu, S H Park, J G Kim, J W Kim, S-H Cho, Y-L Park, S R Park, S Y Rha, M J Kang, J Y Cho, S Y Kang, S Y Roh, B-Y Ryoo, B-H Nam, Y-W Jo, K-E Yoon, S C Oh
Paclitaxel is currently only available as an intravenous (IV) formulation. DHP107 is a novel oral formulation of lipid ingredients and paclitaxel. DHP107 demonstrated comparable efficacy, safety, and pharmacokinetics to IV paclitaxel as second-line therapy in patients with advanced gastric cancer (AGC). DREAM is a multicenter, open-label, prospective, randomized phase III study of patients with histologically/cytologically confirmed, unresectable/recurrent AGC after first-line therapy failure.
Evaluation of the 8th TNM classification on p16-positive oropharyngeal squamous cell carcinomas in the Netherlands, and the importance of additional HPV DNA-testing. Ann. Oncol. (IF 11.855) Pub Date : 2018-02-09 I H Nauta, M M Rietbergen, A A J D van Bokhoven, E Bloemena, B I Witte, D A M Heideman, R J Baatenburg de Jong, R H Brakenhoff, C R Leemans
Oropharyngeal squamous cell carcinomas (OPSCCs) are traditionally caused by smoking and excessive alcohol consumption. However, in the last decades high-risk human papillomavirus (HR-HPV) infections play an increasingly important role in tumorigenesis. HPV-driven OPSCCs are known to have a more favorable prognosis, which has led to important and marked changes in the recently released TNM-8. In this edition, OPSCCs are divided based on p16-immunostaining, with p16-overexpression as surrogate marker for the presence of HPV. The aims of this study are to evaluate TNM-8 on a Dutch consecutive cohort of patients with p16-positive OPSCC and to determine the relevance of additional HPV DNA-testing.
RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study. Ann. Oncol. (IF 11.855) Pub Date : 2018-02-09 J B Bachet, O Bouché, J Taieb, O Dubreuil, M L Garcia, A Meurisse, C Normand, J M Gornet, P Artru, S Louafi, F Bonnetain, A Thirot-Bidault, I Baumgaertner, R Coriat, D Tougeron, T Lecomte, F Mary, T Aparicio, L Marthey, V Taly, H Blons, D Vernerey, P Laurent-Puig
RAS mutations are currently sought for in tumor samples, which takes a median of almost 3 weeks in western European countries. This creates problems in clinical situations that require urgent treatment and for inclusion in therapeutic trials that need RAS status for randomization. Analysis of circulating tumor DNA might help to shorten the time required to determine RAS mutational status prior to anti-EGFR antibody therapy for metastatic colorectal cancer. Here we compared plasma versus tissue RAS analysis in a large prospective multicenter cohort.
The hard road to data interpretation: three or six months of adjuvant chemotherapy for patients with stage III colon cancer? Ann. Oncol. (IF 11.855) Pub Date : 2018-02-09 A Sobrero, A Grothey, T Iveson, R Labianca, T Yoshino, J Taieb, T Maughan, M Buyse, T Andre, J Meyerhardt, A F Shields, I Souglakos, J-Y Douillard, A Cervantes
Six months of adjuvant oxaliplatin-based chemotherapy is standard for patients with stage III colon cancer following surgery. However, oxaliplatin is associated with peripheral neurotoxicity which worsens over treatment duration. Consequently, a shorter treatment duration, if equally effective would be extremely beneficial. A pooled analysis of data for 12,834 stage III colon cancer patients, from six randomised phase III trials of adjuvant therapy, the IDEA study, was performed and the results presented at the ASCO Annual Meeting 2017. To clarify the potential impact of these results on clinical practice ESMO decided to sponsor a special session at their 2017 Annual Meeting dedicated to achieving a more meaningful interpretation of the results.
Lifestyle factors and risk of sporadic colorectal cancer by microsatellite instability status: A systematic review and meta-analyses Ann. Oncol. (IF 11.855) Pub Date : 2018-02-09 P R Carr, E Alwers, S Bienert, J Weberpals, M Kloor, H Brenner, M Hoffmeister
The association of lifestyle factors with molecular pathological subtypes of colorectal cancer (CRC), such as microsatellite instability (MSI), could provide further knowledge about the colorectal carcinogenic process. The aim of this review was to evaluate possible associations between lifestyle factors and risk of sporadic CRC by MSI status.
Final Validation of the ProMisE Molecular Classifier for Endometrial Carcinoma in a Large Population-based Case Series. Ann. Oncol. (IF 11.855) Pub Date : 2018-02-07 S Kommoss, M K McConechy, F Kommoss, S Leung, A Bunz, J Magrill, H Britton, F Kommoss, F Grevenkamp, A Karnezis, W Yang, A Lum, B Krämer, F Taran, A Staebler, S Lax, S Y Brucker, D G Huntsman, C B Gilks, J N McAlpine, A Talhouk
Based on The Cancer Genome Atlas, we previously developed and confirmed a pragmatic molecular classifier for endometrial cancers; ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer). ProMisE identifies four prognostically distinct molecular subtypes, and can be applied to diagnostic specimens (biopsy/curettings), enabling earlier informed decision-making. We have strictly adhered to the Institute of Medicine (IOM) guidelines for the development of genomic biomarkers, and herein present the final validation step of a locked-down classifier prior to clinical application.
Epigenetic modifiers as new immunomodulatory therapies in solid tumours Ann. Oncol. (IF 11.855) Pub Date : 2018-02-07 S Aspeslagh, D Morel, J-C Soria, S Postel-Vinay
Immune therapies have revolutionized cancer treatment over the last few years by allowing improvements in overall survival. However, the majority of patients is still primary or secondary resistant to such therapies, and enhancing sensitivity to immune therapies is therefore crucial to improve patient outcome. Several recent lines of evidence suggest that epigenetic modifiers have intrinsic immunomodulatory properties, which could be of therapeutic interest.
Management of metastatic retroperitoneal sarcoma: a consensus approach from the Transatlantic Retroperitoneal Sarcoma Working Group (TARPSWG) Ann. Oncol. (IF 11.855) Pub Date : 2018-02-07 A J MacNeill, W J Van Houdt, C J Swallow, A Gronchi
Retroperitoneal sarcoma (RPS) is a rare disease accounting for 0.1-0.2% of all malignancies. Management of RPS is complex and requires multidisciplinary, tailored treatment strategies at all stages, but especially in the context of metastatic or multifocal recurrent disease. Due to the rarity and heterogeneity of this family of diseases, the literature to guide management is limited.
Statistical Controversies in Clinical Research: Limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events. A meta-analysis Ann. Oncol. (IF 11.855) Pub Date : 2018-02-05 J C Trone, E Ollier, C Chapelle, L Bertoletti, M Cucherat, P Mismetti, N Magné, S Laporte
Previous meta-analyses have shown paradoxical increased risk of bleeding and thrombotic events in patients receiving antiangiogenics (AA) that may be simply explained by the studies design included. By a meta-epidemiological approach, we aim to investigate the impact of double-blind (DB) and open-label study designs on the risks of bleeding, venous thrombotic events (VTE) and arterial thrombotic events (ATE) in cancer patients treated with AA.
EXPRESSION III: Patient´s Expectations and Preferences regarding Physician–Patient Relationship and Clinical Management. Results of the International NOGGO/ENGOT-ov4-GCIG study in 1,830 Ovarian Cancer Patients from European countries. Ann. Oncol. (IF 11.855) Pub Date : 2018-02-05 G Oskay-Özcelik, S Alavi, R Richter, M Keller, S. C Cecere, G Cormio, F Joly, J. E Kurtz, A du Bois, M Maciejewski, M Jedryka, I Vergote, E Van Nieuwenhuysen, A Casado, C Mendiola, P Achimas-Cadariu, C Vlad, D Reimer, A G Zeimet, M Friedlander, J Sehouli
The primary aim of this study was to investigate information needs and treatment preferences of patients with ovarian cancer, focusing especially on physician-patient relationship and treatment
Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2-positive gastric cancer patients Ann. Oncol. (IF 11.855) Pub Date : 2018-02-02 S T Kim, K C Banks, E Pectasides, S Y Kim, K Kim, R B Lanman, A Talasaz, J An, M G Choi, J H Lee, T S Sohn, J M Bae, S Kim, S H Park, J O Park, Y S Park, H Y Lim, N K D Kim, W Park, H Lee, A J Bass, K Kim, W K Kang, J Lee
To identify predictive markers for responders in lapatinib-treated patients and to demonstrate molecular changes during lapatinib treatment via cell-free genomics.
Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02) Ann. Oncol. (IF 11.855) Pub Date : 2018-02-02 M Tahara, N Kiyota, T Yokota, Y Hasegawa, K Muro, S Takahashi, T Onoe, A Homma, J Taguchi, M Suzuki, K Minato, K Yane, S Ueda, H Hara, K Saijo, T Yamanaka
The standard of care for first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) is combination treatment with platinum, 5-FU and cetuximab (PFE). However, this regimen requires hospitalization to ensure proper hydration and continuous infusion of 5-FU, and causes severe nausea and anorexia. We evaluated the efficacy and safety of paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with R/M SCCHN.
Nivolumab versus docetaxel in previously treated advanced non-small cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases Ann. Oncol. (IF 11.855) Pub Date : 2018-02-02 E E Vokes, N Ready, E Felip, L Horn, M A Burgio, S J Antonia, O Arén Frontera, S Gettinger, E Holgado, D Spigel, D Waterhouse, M Domine, M Garassino, L Q M Chow, G Blumenschein Jr, F Barlesi, B Coudert, J Gainor, O Arrieta, J Brahmer, C Butts, M Steins, W J Geese, A Li, D Healey, L Crinò
Long-term data with immune checkpoint inhibitors in non-small cell lung cancer (NSCLC) are limited. Two phase III trials demonstrated improved overall survival (OS) and a favorable safety profile with the anti–programmed death-1 antibody nivolumab versus docetaxel in patients with previously treated advanced squamous (CheckMate 017) and non-squamous (CheckMate 057) NSCLC. We report results from ≥3 years’ follow-up, including subgroup analyses of patients with liver metastases, who historically have poorer prognosis among patients with NSCLC.
CHK1 Inhibition in Soft-Tissue Sarcomas: Biological and Clinical Implications Ann. Oncol. (IF 11.855) Pub Date : 2018-02-02 A Laroche-Clary, C Lucchesi, C Rey, S Verbeke, A Bourdon, V Chaire, M-P Algéo, S Cousin, M Toulmonde, V Vélasco, J Shutzman, A Savina, F Le Loarer, A Italiano
Inhibition of ChK1 appears as a promising strategy for selectively potentiate the efficacy of chemotherapeutic agents in G1 checkpoint-defective tumor cells such as those that lack functional p53 protein. The p53 pathway is commonly dysregulated in soft-tissue sarcomas (STS) through mutations affecting TP53 or MDM2 amplification. GDC-0575 is a selective ATP-competitive inhibitor of CHK1.
ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma Ann. Oncol. (IF 11.855) Pub Date : 2017-11-29 C Buske, M Hutchings, M Ladetto, V Goede, U Mey, P Soubeyran, M Spina, R Stauder, M Trněný, U Wedding, P Fields, Christian Buske, Martin Dreyling, Andrés J M Ferreri, Paul Fields, Gianluca Gaidano, Valentin Goede, Martin Hutchings, Marco Ladetto, Steven Le Gouill, Stefano Luminari, Ulrich Mey, Peter de Nully Brown, Michael Pfreundschuh, Christiane Pott, Norbert Schmitz, Pierre Soubeyran, Michele Spina, Reinhard Stauder, Anna Sureda Balari, Marek Trněný, Gustaaf van Imhoff, Jan Walewski, Ulrich Wedding, Alberto Zamò, Emanuele Zucca
The European Society for Medical Oncology (ESMO) consensus conference on mature B cell lymphomas and chronic lymphocytic leukaemia (CLL) was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading experts. The aim of the conference was to develop recommendations on critical subjects difficult to consider in detail in the ESMO Clinical Practice Guidelines. The following areas were identified: (1) the elderly patient, (2) prognostic factors suitable for clinical use, and (3) the ‘ultra-high-risk’ group. Before the conference, the expert panel was divided into three working groups; each group focused on one of these areas in order to address clinically-relevant questions relating to that topic. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the consensus conference, each working group developed recommendations to address each of the four questions assigned to their group. These recommendations were presented to the entire panel and a consensus was reached. This consensus, which was further developed in continuous post-meeting discussions, formed the basis of three manuscripts, each covering one of the three key areas identified. This manuscript presents the consensus recommendations regarding the clinical management of elderly patients diagnosed with malignant lymphoma. Four clinically-relevant topics identified by the panel were: 1) how to define patient fitness, 2) assessing quality of life, 3) diagnostic work-up and 4) clinical management of elderly patients with lymphoma. Each of these key topics is addressed in the context of five different lymphoma entities, namely: CLL, follicular lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma and diffuse large B-cell lymphoma. Results, including a summary of evidence supporting each recommendation, are detailed in this manuscript.
Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer Ann. Oncol. (IF 11.855) Pub Date : 2017-11-27 S M de Boer, B G Wortman, T Bosse, M E Powell, N Singh, H Hollema, G Wilson, M N Chowdhury, L Mileshkin, J Pyman, D Katsaros, S Carinelli, A Fyles, C M McLachlin, C Haie-Meder, P Duvillard, R A Nout, K W Verhoeven-Adema, H Putter, C L Creutzberg, V T H B M Smit
In the PORTEC-3 trial, women with high-risk endometrial cancer (HR-EC) were randomised to receive pelvic radiotherapy (RT) with or without concurrent and adjuvant chemotherapy (two cycles of cisplatin 50 mg/m2 in weeks 1 and 4 of RT, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2). Pathology review was required before patient enrolment. The aim of this analysis was to evaluate the role of central pathology review before randomisation.
Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success? Ann. Oncol. (IF 11.855) Pub Date : 2017-11-24 R A Figlin, B C Leibovich, G D Stewart, S Negrier
The success of targeted therapies, including inhibitors of the vascular endothelial growth factor pathway or the mammalian target of rapamycin, in the treatment of metastatic renal cell carcinoma led to interest in testing their efficacy in the adjuvant setting. Results from the first trials are now available, with other studies due to report imminently. This review provides an overview of adjuvant targeted therapy in renal cell carcinoma, including interpretation of currently available conflicting data and future direction of research. We discuss the key differences between the completed targeted therapy adjuvant trials, and highlight the importance of accurately identifying patients who are likely to benefit from adjuvant treatment. We also consider reasons why blinded independent radiology review and treatment dose may prove critical for adjuvant treatment success. The implications of using disease-free survival as a surrogate end point for overall survival from the patient perspective and measurement of health benefit have recently been brought into focus and are discussed. Finally, we discuss how the ongoing adjuvant trials with targeted therapies and checkpoint inhibitors may improve our understanding and ability to prevent tumor recurrence after nephrectomy in the future.
New antiemetics: facing the current challenge Ann. Oncol. (IF 11.855) Pub Date : 2017-11-23 F Scotté
Revolution starts with evolution. Progress regarding emesis has been highlighted by the American Society of Clinical Oncology Committee (https://www.asco.org/about-asco/press-center/news-releases/asco-50th-anniversary-poll-names-top-5-advances-past-50-years) as one of the five leading advances in cancer during the past 50 years. A new generation of antiemetics is approved by the FDA every 10 years leading to a significant enhancement of a no emesis response rate for patients undergoing chemotherapy. We must remember that 100% of cancer-treated patients were impacted by emesis in the seventies, whereas today, ‘only’ 10%–20% of patients are affected [1, 2]. Before the development of setrons (5HT3 receptor antagonists) there was a daily fight by the patient against vomiting. The NK1 inhibitor’s development has radically altered the face of the emesis battle and we...
OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer Ann. Oncol. (IF 11.855) Pub Date : 2017-11-23 D M Provencher, C J Gallagher, W R Parulekar, J A Ledermann, D K Armstrong, M Brundage, C Gourley, I Romero, A Gonzalez-Martin, M Feeney, P Bessette, M Hall, J I Weberpals, G Hall, S K Lau, P Gauthier, M Fung-Kee-Fung, E A Eisenhauer, C Winch, D Tu, H J MacKay
The purpose of this multistage, adaptively, designed randomized phase II study was to evaluate the role of intraperitoneal (i.p.) chemotherapy following neoadjuvant chemotherapy (NACT) and optimal debulking surgery in women with epithelial ovarian cancer (EOC).
Patients’ preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile? Ann. Oncol. (IF 11.855) Pub Date : 2017-11-21 P L Blinman, I D Davis, A Martin, S Troon, S Sengupta, E Hovey, X Coskinas, R Kaplan, A Ritchie, A Meade, T Eisen, M R Stockler
We sought to determine the survival benefits that patients judged sufficient to warrant adjuvant therapy with sorafenib for 1 year, or for 3 years after resection of renal cell carcinoma in the SORCE trial.
Male breast cancer: pink ribbon blues Ann. Oncol. (IF 11.855) Pub Date : 2017-11-20 P A Francis
The pink ribbon is an internationally recognized symbol of breast cancer awareness. However, it has been argued that the colour pink may reinforce the misconception that breast cancer only affects women, potentially leading to delays in the diagnosis of male breast cancer, due to ignorance regarding the significance of male breast cancer signs and symptoms. The lifetime risk of developing breast cancer for men in the general population is 0.1%, and <1% of all breast cancer diagnoses occur in men . Including a blue spot or a blue section in the pink ribbon has been advocated, to signify and acknowledge breast cancer also occurs in men.
Multi-institutional competing risks analysis of distant brain failure and salvage patterns after upfront radiosurgery without whole brain radiotherapy for brain metastasis Ann. Oncol. (IF 11.855) Pub Date : 2017-11-17 E McTyre, D Ayala-Peacock, J Contessa, C Corso, V Chiang, C Chung, J Fiveash, M Ahluwalia, R Kotecha, S Chao, A Attia, A Henson, J Hepel, S Braunstein, M Chan
In this study, we use a competing risks analysis to assess factors predictive of early-salvage whole brain radiotherapy (WBRT) and early death after upfront stereotactic radiosurgery (SRS) alone for brain metastases in an attempt to identify populations that benefit less from upfront SRS.
Improved survival in metastatic germ-cell cancer Ann. Oncol. (IF 11.855) Pub Date : 2017-11-17 C D Fankhauser, S Sander, L Roth, J Beyer, T Hermanns
The prognostic score of the International Germ-Cell Cancer Collaborative Group (IGCCCG) in metastatic germ-cell cancers (mGCC) relies on treatments delivered before 1990. It is unclear, if this score is still relevant to contemporary cohorts of patients who receive modern-type chemotherapy and supportive care.
Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study Ann. Oncol. (IF 11.855) Pub Date : 2017-11-17 A Pettersson, D Robinson, H Garmo, L Holmberg, P Stattin
Old age at prostate cancer diagnosis has been associated with poor prognosis in several studies. We aimed to investigate the association between age at diagnosis and prognosis, and if it is independent of tumor characteristics, primary treatment, year of diagnosis, mode of detection and comorbidity.
Nivolumab in non-small-cell lung cancer with EGFR mutation Ann. Oncol. (IF 11.855) Pub Date : 2017-11-17 H Yoshida, Y H Kim, H Ozasa, H Nagai, Y Sakamori, T Tsuji, T Nomizo, Y Yasuda, T Funazo, T Hirai
Inhibitors of the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) axis are the newest treatment option for metastatic non-small-cell lung cancer (NSCLC). Nivolumab, the first approved PD-1 inhibitor, demonstrated significant survival benefits compared with standard chemotherapy in the second-line setting for both squamous (Checkmate 017) and non-squamous (Checkmate 057) NSCLC. However, subgroup analysis of the Checkmate 057 study revealed that this survival advantage was not observed in patients with epidermal growth factor receptor (EGFR) mutations . This observation was confirmed in the meta-analysis, including three randomized trials comparing PD-1/PD-L1 inhibitors with docetaxel . Currently, it is widely accepted that PD-1/PD-L1 inhibitors are not as effective in patients with EGFR mutations as in patients with wild-type EGFR....
Reply to the letter to the editor ‘Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies’ Ann. Oncol. (IF 11.855) Pub Date : 2017-11-17 N I Cherny, U Dafni, J Bogaerts, N J Latino, G Pentheroudakis, J -Y Douillard, J Tabernero, C Zielinski, M J Piccart, E G E de Vries
We appreciate the ongoing interest and contributions of Dr Del Paggio and his colleagues in the development of clinical benefit scales. In this letter , they report that the relatively low correlation of ‘clinically meaningful benefit’ identified using the American Society of Clinical Oncology (ASCO) Value Framework v2 and ESMO-MCBS v1.0 that they have previously described , is slightly improved using the new ESMO-MCBS v1.1.
Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial Ann. Oncol. (IF 11.855) Pub Date : 2017-11-14 L Buisseret, S Pommey, B Allard, S Garaud, M Bergeron, I Cousineau, L Ameye, Y Bareche, M Paesmans, J P A Crown, A Di Leo, S Loi, M Piccart-Gebhart, K Willard-Gallo, C Sotiriou, J Stagg
CD73 is an ecto-enzyme that promotes tumor immune escape through the production of immunosuppressive extracellular adenosine in the tumor microenvironment. Several CD73 inhibitors and adenosine receptor antagonists are being evaluated in phase I clinical trials.
Outcome prediction in patients with localized soft tissue sarcoma: which tool is the best? Ann. Oncol. (IF 11.855) Pub Date : 2017-11-14 B Kasper, E Wardelmann
Soft tissue sarcomas (STS) are rare malignancies of mesenchymal origin comprising ∼1% of all adult cancers. According to the 2013 updated World Health Organization (WHO) classification STS represents a highly heterogeneous tumor entity of more than 50 subtypes showing very distinct histologic, molecular and certainly clinical characteristics . Surgery is the mainstay of treatment of localized disease, however, around 50% of patients experience metastatic recurrence during the course of their disease. This disease stage is still characterized by an unfavorable prognosis and a median overall survival of ∼12–15 months [2, 3]. Due to conflicting data, adjuvant chemotherapy is not a standard treatment in STS in adulthood , but may be offered to the cohort of high-risk patients—tumor...
Human papillomavirus (HPV) and somatic EGFR mutations are essential, mutually exclusive oncogenic mechanisms for inverted sinonasal papillomas and associated sinonasal squamous cell carcinomas Ann. Oncol. (IF 11.855) Pub Date : 2017-11-14 A M Udager, J B McHugh, C M Goudsmit, H C Weigelin, M S Lim, K S J Elenitoba-Johnson, B L Betz, T E Carey, N A Brown
Inverted sinonasal (Schneiderian) papilloma (ISP) is a locally aggressive neoplasm often associated with sinonasal squamous cell carcinoma (SNSCC). While the etiology of ISP is not well understood, human papillomavirus (HPV) has been detected in a subset of cases. Our group recently identified activating somatic EGFR mutations in the majority of ISP and ISP-associated SNSCC. However, the relationship between EGFR mutations and HPV infection has not been explored.
Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial Ann. Oncol. (IF 11.855) Pub Date : 2017-11-14 A Abad, E Martínez-Balibrea, J M Viéitez, V Alonso-Orduña, P García Alfonso, J L Manzano, B Massutí, M Benavides, A Carrato, M Zanui, J Gallego, C Grávalos, V Conde, M Provencio, M Valladares-Ayerbes, R Salazar, J Sastre, C Montagut, F Rivera, E Aranda
There has been little progress toward personalized therapy for patients with metastatic colorectal cancer (mCRC). TYMS-3′ untranslated region (UTR) 6 bp ins/del and ERCC1-118C/T polymorphisms were previously reported to facilitate selecting patients for fluoropyrimidine-based treatment in combination with oxaliplatin as first-line therapy. We assessed the utility of these markers in selecting therapy for patients with mCRC.
Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors Ann. Oncol. (IF 11.855) Pub Date : 2017-11-10 C Albany, N Adra, A C Snavely, C Cary, T A Masterson, R S Foster, K Kesler, T M Ulbright, L Cheng, M Chovanec, F Taza, K Ku, M J Brames, N H Hanna, L H Einhorn
To report our experience utilizing a multidisciplinary clinic (MDC) at Indiana University (IU) since the publication of the International Germ Cell Cancer Collaborative Group (IGCCCG), and to compare our overall survival (OS) to that of the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program.
Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II Ann. Oncol. (IF 11.855) Pub Date : 2017-11-06 I Sestak, S G Smith, A Howell, J F Forbes, J Cuzick
Anastrozole reduces breast cancer risk in women at high risk, but implementing preventive therapy in clinical practice is difficult. Here, we evaluate adherence to anastrozole in the International Breast Cancer Intervention Study (IBIS)-II prevention and ductal carcinoma in situ (DCIS) trials, and its association with early symptoms.
Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial Ann. Oncol. (IF 11.855) Pub Date : 2017-11-06 B J Noordman, M G E Verdam, S M Lagarde, J Shapiro, M C C M Hulshof, M I van Berge Henegouwen, B P L Wijnhoven, G A P Nieuwenhuijzen, J J Bonenkamp, M A Cuesta, J Th M Plukker, E J Spillenaar Bilgen, E W Steyerberg, A van der Gaast, M A G Sprangers, J J B van Lanschot
Neoadjuvant chemoradiotherapy (nCRT) plus surgery is a standard of care for patients with esophageal or junctional cancer, but the long-term impact of nCRT on health-related quality of life (HRQOL) is unknown. The purpose of this study is to compare very long-term HRQOL in long-term survivors of esophageal cancer who received nCRT plus surgery or surgery alone.
Goserelin does not preserve ovarian function against chemotherapy-induced damage Ann. Oncol. (IF 11.855) Pub Date : 2017-11-03 K Oktay, E Taylan, K A Rodriguez-Wallberg, G Bedoschi, V Turan, F Pacheco
In this randomized trial of Goserelin for ovarian protection during adjuvant chemotherapy in women with breast cancer, Leonard et al. concluded that ovarian suppression may reduce likelihood of amenorrhea and Premature Ovarian Insufficiency (POI) in those aged <40 years . However, we are concerned about the validity of these conclusions.
Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma Ann. Oncol. (IF 11.855) Pub Date : 2017-11-03 R J Lee, G Gremel, A Marshall, K A Myers, N Fisher, J A Dunn, N Dhomen, P G Corrie, M R Middleton, P Lorigan, R Marais
Patients with high-risk stage II/III resected melanoma commonly develop distant metastases. At present, we cannot differentiate between patients who will recur or those who are cured by surgery. We investigated if circulating tumor DNA (ctDNA) can predict relapse and survival in patients with resected melanoma.
Some contents have been Reproduced by permission of The Royal Society of Chemistry.
- Acc. Chem. Res.
- ACS Appl. Mater. Interfaces
- ACS Biomater. Sci. Eng.
- ACS Catal.
- ACS Cent. Sci.
- ACS Chem. Biol.
- ACS Chem. Neurosci.
- ACS Comb. Sci.
- ACS Earth Space Chem.
- ACS Energy Lett.
- ACS Infect. Dis.
- ACS Macro Lett.
- ACS Med. Chem. Lett.
- ACS Nano
- ACS Omega
- ACS Photonics
- ACS Sens.
- ACS Sustainable Chem. Eng.
- ACS Synth. Biol.
- Acta Biomater.
- Acta Crystallogr. A Found. Adv.
- Acta Mater.
- Adv. Colloid Interface Sci.
- Adv. Electron. Mater.
- Adv. Energy Mater.
- Adv. Funct. Mater.
- Adv. Healthcare Mater.
- Adv. Mater.
- Adv. Mater. Interfaces
- Adv. Opt. Mater.
- Adv. Sci.
- Adv. Synth. Catal.
- AlChE J.
- Anal. Bioanal. Chem.
- Anal. Chem.
- Anal. Chim. Acta
- Anal. Methods
- Angew. Chem. Int. Ed.
- Annu. Rev. Anal. Chem.
- Annu. Rev. Biochem.
- Annu. Rev. Environ. Resour.
- Annu. Rev. Food Sci. Technol.
- Annu. Rev. Mater. Res.
- Annu. Rev. Phys. Chem.
- Appl. Catal. A Gen.
- Appl. Catal. B Environ.
- Appl. Clay. Sci.
- Appl. Energy
- Aquat. Toxicol.
- Arab. J. Chem.
- Asian J. Org. Chem.
- Atmos. Environ.
- Carbohydr. Polym.
- Catal. Commun.
- Catal. Rev. Sci. Eng.
- Catal. Sci. Technol.
- Catal. Today
- Cell Chem. Bio.
- Cem. Concr. Res.
- Ceram. Int.
- Chem. Asian J.
- Chem. Bio. Drug Des.
- Chem. Biol. Interact.
- Chem. Commun.
- Chem. Educ. Res. Pract.
- Chem. Eng. J.
- Chem. Eng. Sci.
- Chem. Eur. J.
- Chem. Mater.
- Chem. Phys.
- Chem. Phys. Lett.
- Chem. Phys. Lipids
- Chem. Rev.
- Chem. Sci.
- Chem. Soc. Rev.
- Chin. J. Chem.
- Combust. Flame
- Compos. Part A Appl. Sci. Manuf.
- Compos. Sci. Technol.
- Compr. Rev. Food Sci. Food Saf.
- Comput. Chem. Eng.
- Constr. Build. Mater.
- Coordin. Chem. Rev.
- Corros. Sci.
- Crit. Rev. Food Sci. Nutr.
- Crit. Rev. Solid State Mater. Sci.
- Cryst. Growth Des.
- Curr. Opin. Chem. Eng.
- Curr. Opin. Colloid Interface Sci.
- Curr. Opin. Environ. Sustain
- Curr. Opin. Solid State Mater. Sci.
- Ecotox. Environ. Safe.
- Electrochem. Commun.
- Electrochim. Acta
- Energy Environ. Sci.
- Energy Fuels
- Energy Storage Mater.
- Environ. Impact Assess. Rev.
- Environ. Int.
- Environ. Model. Softw.
- Environ. Pollut.
- Environ. Res.
- Environ. Sci. Policy
- Environ. Sci. Technol.
- Environ. Sci. Technol. Lett.
- Environ. Sci.: Nano
- Environ. Sci.: Processes Impacts
- Environ. Sci.: Water Res. Technol.
- Eur. J. Inorg. Chem.
- Eur. J. Med. Chem.
- Eur. J. Org. Chem.
- Eur. Polym. J.
- J. Acad. Nutr. Diet.
- J. Agric. Food Chem.
- J. Alloys Compd.
- J. Am. Ceram. Soc.
- J. Am. Chem. Soc.
- J. Am. Soc. Mass Spectrom.
- J. Anal. Appl. Pyrol.
- J. Anal. At. Spectrom.
- J. Antibiot.
- J. Catal.
- J. Chem. Educ.
- J. Chem. Eng. Data
- J. Chem. Inf. Model.
- J. Chem. Phys.
- J. Chem. Theory Comput.
- J. Chromatogr. A
- J. Chromatogr. B
- J. Clean. Prod.
- J. CO2 UTIL.
- J. Colloid Interface Sci.
- J. Comput. Chem.
- J. Cryst. Growth
- J. Dairy Sci.
- J. Electroanal. Chem.
- J. Electrochem. Soc.
- J. Environ. Manage.
- J. Eur. Ceram. Soc.
- J. Fluorine Chem.
- J. Food Drug Anal.
- J. Food Eng.
- J. Food Sci.
- J. Funct. Foods
- J. Hazard. Mater.
- J. Heterocycl. Chem.
- J. Hydrol.
- J. Ind. Eng. Chem.
- J. Inorg. Biochem.
- J. Magn. Magn. Mater.
- J. Mater. Chem. A
- J. Mater. Chem. B
- J. Mater. Chem. C
- J. Mater. Process. Tech.
- J. Mech. Behav. Biomed. Mater.
- J. Med. Chem.
- J. Membr. Sci.
- J. Mol. Catal. A Chem.
- J. Mol. Liq.
- J. Nat. Gas Sci. Eng.
- J. Nat. Prod.
- J. Nucl. Mater.
- J. Org. Chem.
- J. Photochem. Photobiol. C Photochem. Rev.
- J. Phys. Chem. A
- J. Phys. Chem. B
- J. Phys. Chem. C
- J. Phys. Chem. Lett.
- J. Polym. Sci. A Polym. Chem.
- J. Porphyr. Phthalocyanines
- J. Power Sources
- J. Solid State Chem.
- J. Taiwan Inst. Chem. E.
- Macromol. Rapid Commun.
- Mass Spectrom. Rev.
- Mater. Chem. Front.
- Mater. Des.
- Mater. Horiz.
- Mater. Lett.
- Mater. Sci. Eng. A
- Mater. Sci. Eng. R Rep.
- Mater. Today
- Meat Sci.
- Med. Chem. Commun.
- Microchem. J.
- Microchim. Acta
- Micropor. Mesopor. Mater.
- Mol. Biosyst.
- Mol. Cancer Ther.
- Mol. Catal.
- Mol. Nutr. Food Res.
- Mol. Pharmaceutics
- Mol. Syst. Des. Eng.
- Nano Energy
- Nano Lett.
- Nano Res.
- Nano Today
- Nano-Micro Lett.
- Nanomed. Nanotech. Biol. Med.
- Nanoscale Horiz.
- Nat. Catal.
- Nat. Chem.
- Nat. Chem. Biol.
- Nat. Commun.
- Nat. Energy
- Nat. Mater.
- Nat. Med.
- Nat. Methods
- Nat. Nanotech.
- Nat. Photon.
- Nat. Prod. Rep.
- Nat. Protoc.
- Nat. Rev. Chem.
- Nat. Rev. Drug. Disc.
- Nat. Rev. Mater.
- Natl. Sci. Rev.
- Neurochem. Int.
- New J. Chem.
- NPG Asia Mater.
- npj 2D Mater. Appl.
- npj Comput. Mater.
- npj Flex. Electron.
- npj Mater. Degrad.
- npj Sci. Food
- Pharmacol. Rev.
- Pharmacol. Therapeut.
- Photochem. Photobiol. Sci.
- Phys. Chem. Chem. Phys.
- Phys. Life Rev.
- PLOS ONE
- Polym. Chem.
- Polym. Degrad. Stabil.
- Polym. J.
- Polym. Rev.
- Powder Technol.
- Proc. Combust. Inst.
- Prog. Cryst. Growth Ch. Mater.
- Prog. Energy Combust. Sci.
- Prog. Mater. Sci.
- Prog. Photovoltaics
- Prog. Polym. Sci.
- Prog. Solid State Chem.
- Sci. Adv.
- Sci. Bull.
- Sci. Rep.
- Sci. Total Environ.
- Sci. Transl. Med.
- Scr. Mater.
- Sens Actuators B Chem.
- Sep. Purif. Technol.
- Small Methods
- Soft Matter
- Sol. Energy
- Sol. Energy Mater. Sol. Cells
- Solar PRL
- Spectrochim. Acta. A Mol. Biomol. Spectrosc.
- Surf. Sci. Rep.
- Sustainable Energy Fuels